Effective Capture of Circulating Tumor Cells from a Transgenic Mouse Lung Cancer Model Using Dendrimer Surfaces Immobilized with Anti-EGFR

Ja Hye Myung, Monic Roengvoraphoj, Kevin A. Tam, Tian Ma, Vincent A. Memoli, Ethan Dmitrovsky, Sarah J. Freemantle, Seungpyo Hong

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The lack of an effective detection method for lung circulating tumor cells (CTCs) presents a substantial challenge to elucidate the value of CTCs as a diagnostic or prognostic indicator in lung cancer, particularly in nonsmall cell lung cancer (NSCLC). In this study, we prepared a capture surface exploiting strong multivalent binding mediated by poly(amidoamine) (PAMAM) dendrimers to capture CTCs originating from lung cancers. Given that 85% of the tumor cells from NSCLC patients overexpress epidermal growth factor receptor (EGFR), anti-EGFR was chosen as a capture agent. Following in vitro confirmation using the murine lung cancer cell lines (ED-1 and ED1-SC), cyclin E-overexpressing (CEO) transgenic mice were employed as an in vivo lung tumor model to assess specificity and sensitivity of the capture surface. The numbers of CTCs in blood from the CEO transgenic mice were significantly higher than those from the healthy controls (on average 75.3 ± 14.9 vs 4.4 ± 1.2 CTCs/100 μL of blood, p < 0.005), indicating the high sensitivity and specificity of our surface. Furthermore, we found that the capture surface also offers a simple, effective method for monitoring treatment responses, as observed by the significant decrease in the CTC numbers from the CEO mice upon a treatment using a novel anti-miR-31 locked nucleic acid (LNA), compared to a vehicle treatment and a control-LNA treatment (p < 0.05). This in vivo evaluation study confirms that our capture surface is highly efficient in detecting in vivo CTCs and thus has translational potential as a diagnostic and prognostic tool for lung cancer.

Original languageEnglish
Pages (from-to)10096-10102
Number of pages7
JournalAnalytical Chemistry
Volume87
Issue number19
DOIs
Publication statusPublished - 2015 Oct 6

Fingerprint

Dendrimers
Epidermal Growth Factor Receptor
Tumors
Cells
Cyclin E
Blood

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry

Cite this

Myung, Ja Hye ; Roengvoraphoj, Monic ; Tam, Kevin A. ; Ma, Tian ; Memoli, Vincent A. ; Dmitrovsky, Ethan ; Freemantle, Sarah J. ; Hong, Seungpyo. / Effective Capture of Circulating Tumor Cells from a Transgenic Mouse Lung Cancer Model Using Dendrimer Surfaces Immobilized with Anti-EGFR. In: Analytical Chemistry. 2015 ; Vol. 87, No. 19. pp. 10096-10102.
@article{63f577247cb1473d8435ae9c76a361a3,
title = "Effective Capture of Circulating Tumor Cells from a Transgenic Mouse Lung Cancer Model Using Dendrimer Surfaces Immobilized with Anti-EGFR",
abstract = "The lack of an effective detection method for lung circulating tumor cells (CTCs) presents a substantial challenge to elucidate the value of CTCs as a diagnostic or prognostic indicator in lung cancer, particularly in nonsmall cell lung cancer (NSCLC). In this study, we prepared a capture surface exploiting strong multivalent binding mediated by poly(amidoamine) (PAMAM) dendrimers to capture CTCs originating from lung cancers. Given that 85{\%} of the tumor cells from NSCLC patients overexpress epidermal growth factor receptor (EGFR), anti-EGFR was chosen as a capture agent. Following in vitro confirmation using the murine lung cancer cell lines (ED-1 and ED1-SC), cyclin E-overexpressing (CEO) transgenic mice were employed as an in vivo lung tumor model to assess specificity and sensitivity of the capture surface. The numbers of CTCs in blood from the CEO transgenic mice were significantly higher than those from the healthy controls (on average 75.3 ± 14.9 vs 4.4 ± 1.2 CTCs/100 μL of blood, p < 0.005), indicating the high sensitivity and specificity of our surface. Furthermore, we found that the capture surface also offers a simple, effective method for monitoring treatment responses, as observed by the significant decrease in the CTC numbers from the CEO mice upon a treatment using a novel anti-miR-31 locked nucleic acid (LNA), compared to a vehicle treatment and a control-LNA treatment (p < 0.05). This in vivo evaluation study confirms that our capture surface is highly efficient in detecting in vivo CTCs and thus has translational potential as a diagnostic and prognostic tool for lung cancer.",
author = "Myung, {Ja Hye} and Monic Roengvoraphoj and Tam, {Kevin A.} and Tian Ma and Memoli, {Vincent A.} and Ethan Dmitrovsky and Freemantle, {Sarah J.} and Seungpyo Hong",
year = "2015",
month = "10",
day = "6",
doi = "10.1021/acs.analchem.5b02766",
language = "English",
volume = "87",
pages = "10096--10102",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "19",

}

Effective Capture of Circulating Tumor Cells from a Transgenic Mouse Lung Cancer Model Using Dendrimer Surfaces Immobilized with Anti-EGFR. / Myung, Ja Hye; Roengvoraphoj, Monic; Tam, Kevin A.; Ma, Tian; Memoli, Vincent A.; Dmitrovsky, Ethan; Freemantle, Sarah J.; Hong, Seungpyo.

In: Analytical Chemistry, Vol. 87, No. 19, 06.10.2015, p. 10096-10102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effective Capture of Circulating Tumor Cells from a Transgenic Mouse Lung Cancer Model Using Dendrimer Surfaces Immobilized with Anti-EGFR

AU - Myung, Ja Hye

AU - Roengvoraphoj, Monic

AU - Tam, Kevin A.

AU - Ma, Tian

AU - Memoli, Vincent A.

AU - Dmitrovsky, Ethan

AU - Freemantle, Sarah J.

AU - Hong, Seungpyo

PY - 2015/10/6

Y1 - 2015/10/6

N2 - The lack of an effective detection method for lung circulating tumor cells (CTCs) presents a substantial challenge to elucidate the value of CTCs as a diagnostic or prognostic indicator in lung cancer, particularly in nonsmall cell lung cancer (NSCLC). In this study, we prepared a capture surface exploiting strong multivalent binding mediated by poly(amidoamine) (PAMAM) dendrimers to capture CTCs originating from lung cancers. Given that 85% of the tumor cells from NSCLC patients overexpress epidermal growth factor receptor (EGFR), anti-EGFR was chosen as a capture agent. Following in vitro confirmation using the murine lung cancer cell lines (ED-1 and ED1-SC), cyclin E-overexpressing (CEO) transgenic mice were employed as an in vivo lung tumor model to assess specificity and sensitivity of the capture surface. The numbers of CTCs in blood from the CEO transgenic mice were significantly higher than those from the healthy controls (on average 75.3 ± 14.9 vs 4.4 ± 1.2 CTCs/100 μL of blood, p < 0.005), indicating the high sensitivity and specificity of our surface. Furthermore, we found that the capture surface also offers a simple, effective method for monitoring treatment responses, as observed by the significant decrease in the CTC numbers from the CEO mice upon a treatment using a novel anti-miR-31 locked nucleic acid (LNA), compared to a vehicle treatment and a control-LNA treatment (p < 0.05). This in vivo evaluation study confirms that our capture surface is highly efficient in detecting in vivo CTCs and thus has translational potential as a diagnostic and prognostic tool for lung cancer.

AB - The lack of an effective detection method for lung circulating tumor cells (CTCs) presents a substantial challenge to elucidate the value of CTCs as a diagnostic or prognostic indicator in lung cancer, particularly in nonsmall cell lung cancer (NSCLC). In this study, we prepared a capture surface exploiting strong multivalent binding mediated by poly(amidoamine) (PAMAM) dendrimers to capture CTCs originating from lung cancers. Given that 85% of the tumor cells from NSCLC patients overexpress epidermal growth factor receptor (EGFR), anti-EGFR was chosen as a capture agent. Following in vitro confirmation using the murine lung cancer cell lines (ED-1 and ED1-SC), cyclin E-overexpressing (CEO) transgenic mice were employed as an in vivo lung tumor model to assess specificity and sensitivity of the capture surface. The numbers of CTCs in blood from the CEO transgenic mice were significantly higher than those from the healthy controls (on average 75.3 ± 14.9 vs 4.4 ± 1.2 CTCs/100 μL of blood, p < 0.005), indicating the high sensitivity and specificity of our surface. Furthermore, we found that the capture surface also offers a simple, effective method for monitoring treatment responses, as observed by the significant decrease in the CTC numbers from the CEO mice upon a treatment using a novel anti-miR-31 locked nucleic acid (LNA), compared to a vehicle treatment and a control-LNA treatment (p < 0.05). This in vivo evaluation study confirms that our capture surface is highly efficient in detecting in vivo CTCs and thus has translational potential as a diagnostic and prognostic tool for lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84943145653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943145653&partnerID=8YFLogxK

U2 - 10.1021/acs.analchem.5b02766

DO - 10.1021/acs.analchem.5b02766

M3 - Article

C2 - 26312815

AN - SCOPUS:84943145653

VL - 87

SP - 10096

EP - 10102

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 19

ER -